Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 7Prostatic Neoplasms 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Thyroid Nodule 1Thyroid Neoplasms 1Thyroid Diseases 1Skin Neoplasms 1Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 41Paclitaxel 32Radiotherapy 28Cisplatin 25Bevacizumab 24Erlotinib Hydrochloride 19Pemetrexed 18Docetaxel 16Gemcitabine 15Gefitinib 8Vinorelbine 7Taxes 7Cetuximab 7ceritinib 5Surgical Procedures, Operative 5Etoposide 5Amplified Fragment Length Polymorphism Analysis 5sargramostim 3pembrolizumab 3capmatinib 3Radiotherapy, Conformal 3Radiation 3Gene Expression Profiling 3Cyclophosphamide 32-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a 3trametinib 2pegfilgrastim 2osimertinib 2Topotecan 2Tirapazamine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adenocarcinoma of Lung × Biopsy, Needle × Clear all
NCT01259089 2019-09-11

Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

Northwestern University

Phase 1/2 Completed
38 enrolled 12 charts
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡